Alopexx, Inc. (ALPX)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -956,954 |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ALPX
Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). To date over 75 separate pathogens have been found to express PNAG. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow...
Financial Performance
Financial StatementsNews
Alopexx IPO Registration Document (S-1)
Alopexx has filed to go public with an IPO on the NASDAQ.
Biopharma financings cut by a third, transactions track with 2019 and earlier
Financings in the first two months of 2022 amount to only a third of the money raised during the same timeframe of 2021 and the number of transactions is down by 56 percent.
Infectious disease biotech Alopexx files for a $17 million IPO
Alopexx, a Phase 2 biotech developing immune therapies for bacterial, fungal, and parasitic infections, filed on Monday with the SEC to raise up to $17 million in an initial public offering.